marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Soleno Therapeutics Balance Sheet 2011-2024 | SLNO
Annual Balance Sheet Soleno Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-20.8 M | -49.1 M | -20.4 M | -23.1 M | -17.1 M | -2.73 M | -5.49 M | -7.86 M | 12.7 M | 8.98 M | - | |
Long Term Debt |
- | 175 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
155 K | 282 K | 139 K | 305 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 10.8 M | 18.3 M | 10.9 M | 10.8 M | 422 K | 1.78 M | 17.4 M | 25.3 M | 25.2 M | - |
Total Current Liabilities |
7.31 M | 8.01 M | 8.62 M | 4.96 M | 1.88 M | 1.73 M | 1.71 M | 3.19 M | 1.29 M | - | - | - |
Total Liabilities |
16.1 M | 17.8 M | 19.4 M | 23.2 M | 12.7 M | 12.5 M | 2.13 M | 4.98 M | 18.7 M | 39.5 M | 36.7 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-237 M | -213 M | -182 M | -158 M | -127 M | -114 M | -98.3 M | -86.2 M | -71 M | -57.1 M | -53.4 M | - |
Total Assets |
26.5 M | 35.6 M | 65 M | 38.2 M | 43.2 M | 39 M | 5.56 M | 8.2 M | 8.4 M | 1.59 M | 2.51 M | - |
Cash and Cash Equivalents |
14.6 M | 21.3 M | 49.2 M | 20.7 M | 23.1 M | 17.1 M | 2.73 M | 5.49 M | 7.96 M | 1.27 M | - | - |
Book Value |
10.3 M | 17.8 M | 45.5 M | 14.9 M | 30.4 M | 26.5 M | 3.44 M | 3.22 M | -10.3 M | -37.9 M | -34.2 M | - |
Total Shareholders Equity |
10.3 M | 17.8 M | 45.5 M | 14.9 M | 30.4 M | 26.8 M | 3.44 M | 3.22 M | -11.2 M | -37.9 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Soleno Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.58 M | - | 37 K | 130 K | - | 273 K | - | - | - | - | 79 K | 175 K | 274 K | 372 K | - | - | - | - | - | 8 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.55 M | 3.05 M | 20.3 M | 18.3 M | - | 18.3 M | 18.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
32 M | 23.4 M | 25.5 M | 23.2 M | - | 18.5 M | 16.9 M | 16.1 M | 16.8 M | 16.6 M | 16.1 M | 17.8 M | 22.4 M | 21.3 M | 19.1 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.2 M | 12.2 M | 12.5 M | 12.5 M | 2.13 M | 2.13 M | 2.13 M | 2.13 M | 4.98 M | 8.58 M | 16.4 M | 21.4 M | 19.6 M | - | 19.6 M | 19.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-396 M | -320 M | -298 M | -276 M | - | -254 M | -246 M | -237 M | -232 M | -226 M | -219 M | -213 M | -211 M | -202 M | -191 M | -182 M | -182 M | -182 M | -182 M | -158 M | -158 M | -158 M | -158 M | -127 M | -127 M | -127 M | -127 M | -114 M | -114 M | -114 M | -114 M | -98.3 M | -98.3 M | -98.3 M | -98.3 M | -86.2 M | -86.2 M | -86.2 M | -86.2 M | -70.3 M | -70.3 M | -70.3 M | -70.3 M | -57.1 M | -57.1 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
297 M | 304 M | 169 M | 181 M | - | 30.9 M | 19.5 M | 26.5 M | 32 M | 36.9 M | 42.5 M | 35.6 M | 42.6 M | 48.8 M | 56.7 M | 65 M | 65 M | 65 M | 65 M | 38.2 M | 38.2 M | 38.2 M | 38.2 M | 43.2 M | 43.2 M | 43.2 M | 43.2 M | 39 M | 39 M | 39 M | 39 M | 5.56 M | 5.56 M | 5.56 M | 5.56 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 1.59 M | 1.59 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
48.4 M | 57 M | 42.8 M | 170 M | 52.4 M | 19.4 M | 7.87 M | 14.6 M | 19.8 M | 24.1 M | 29 M | 21.3 M | 28.2 M | 33.6 M | 41.6 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 2.73 M | 2.73 M | 2.73 M | 2.73 M | 5.49 M | 5.5 M | 5.5 M | 5.5 M | 7.96 M | 7.96 M | 7.96 M | 7.96 M | 1.27 M | 1.27 M | - | - | 2.16 M | - | - | - | - | - | - | - |
Book Value |
265 M | 281 M | 143 M | 158 M | - | 12.4 M | 2.64 M | 10.3 M | 15.2 M | 20.3 M | 26.5 M | 17.8 M | 20.2 M | 27.4 M | 37.6 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 26.8 M | 26.8 M | 26.5 M | 26.5 M | 3.44 M | 3.44 M | 3.44 M | 3.44 M | 3.22 M | -378 K | -8.2 M | -13.2 M | -11.2 M | 8.4 M | -11.2 M | -11.2 M | 1.59 M | 1.59 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
265 M | 281 M | 143 M | 158 M | 23.2 M | 12.4 M | 2.64 M | 10.3 M | 15.2 M | 20.3 M | 26.5 M | 17.8 M | 20.2 M | 27.4 M | 37.6 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 26.8 M | 26.8 M | 26.5 M | 26.5 M | 3.44 M | 3.44 M | 3.44 M | 3.44 M | 3.22 M | 3.22 M | 3.22 M | 3.22 M | -11.2 M | -11.2 M | -11.2 M | -11.2 M | -34.2 M | -37.9 M | - | - | -34.2 M | - | - | - | - | - | - | - |
All numbers in USD currency